Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice

Hum Vaccin Immunother. 2014;10(10):2885-95. doi: 10.4161/hv.29823.

Abstract

Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) have caused severe epidemics of hand, foot and mouth disease (HFMD) in the Asia Pacific in recent years, particularly in infants and young children. This disease has become a serious public health problem, as no vaccines or antiviral drugs have been approved for EV71 and CA16 infections. In this study, we compared four monovalent vaccines, including formalin-inactivated EV71 virus (iEV71), EV71 virus-like particles (VLPs) (vEV71), formalin-inactivated CVA16 virus (iCVA16) and CVA16 VLPs (vCVA16), along with two bivalent vaccines, including equivalent doses of formalin-inactivated EV71+CVA16 virus (iEV71+iCVA16) and EV71+CVA16 VLPs (vEV71+vCVA16). The IgG titers and neutralization antibodies titers demonstrated that there are no immune interference exists between the two immunogens of EV71 and CVA16. IgG subclass isotyping revealed that IgG1 and IgG2b were induced primarily in all vaccine groups. Furthermore, cross-neutralization antibodies were elicited in mouse sera against other sub-genotypes of EV71 and CVA16. In vivo challenge experiments showed that the immune sera from vaccinated animals could confer passive protection to newborn mice against lethal challenge with 14 LD50 of EV71 and 50 LD50 of CVA16. Our results indicated that bivalent vaccination is promising for HFMD vaccine development. With the advantage of having a better safety profile than inactivated virus vaccines, VLPs should be used to combine both EV71 and CVA16 antigens as a candidate vaccine for prevention of HFMD virus transmission.

Keywords: Coxsackievirus A16; Enterovirus 71; HFMD; bivalent vaccines; monovalent vaccine; pseudovirus.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Coxsackievirus Infections / immunology
  • Coxsackievirus Infections / prevention & control*
  • Enterovirus A, Human / immunology*
  • Hand, Foot and Mouth Disease / immunology
  • Hand, Foot and Mouth Disease / prevention & control
  • Immunization, Passive
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Mice
  • Neutralization Tests
  • Vaccination
  • Vaccines, Inactivated / immunology*
  • Vaccines, Inactivated / therapeutic use
  • Viral Vaccines / immunology*
  • Viral Vaccines / therapeutic use

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G
  • Vaccines, Inactivated
  • Viral Vaccines